TSE:I Intellipharmaceutics International (I) Stock Price, News & Analysis → The Hidden Tax Advantages of America’s #1 Inheritance Stock (From Stansberry Research) (Ad) Free I Stock Alerts Add Compare Share Share Today's Range N/A50-Day RangeC$3.23▼C$3.2352-Week Range N/AVolume7,625 shsAverage Volume16,872 shsMarket CapitalizationC$97.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Intellipharmaceutics International alerts: Email Address Ad Stansberry ResearchThe Hidden Tax Advantages of America’s #1 Inheritance StockWall Street Millionaire: BUY "America's #1 Legacy Stock" The man CNBC called "The Prophet" bought AAPL at $0.35, AMZN under $2.50, and NVDA before it soared 1,200%. Recently, he sat down for an exclusive interview, revealing EXACTLY where to put your money this year. An investment vehicle he's so confident in, he says he'd put 50% of his kids' inheritance into this stock.You can get the name and ticker symbol, absolutely free, right here. About Intellipharmaceutics InternationalIntellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.Read More Ad Stansberry ResearchThe Hidden Tax Advantages of America’s #1 Inheritance StockWall Street Millionaire: BUY "America's #1 Legacy Stock" The man CNBC called "The Prophet" bought AAPL at $0.35, AMZN under $2.50, and NVDA before it soared 1,200%. Recently, he sat down for an exclusive interview, revealing EXACTLY where to put your money this year. An investment vehicle he's so confident in, he says he'd put 50% of his kids' inheritance into this stock.You can get the name and ticker symbol, absolutely free, right here. I Stock News HeadlinesApril 22, 2024 | finance.yahoo.comSuper Generics Market Size Will Reach USD 128.62 Billion to 2031 - Revealed InsightAce Latest StudyFebruary 19, 2024 | theglobeandmail.comIntelliPharmaCeutics Intl: Top 10 Undervalued Biotechnology Industry Stocks (IPCI)January 3, 2024 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc up on Wednesday (IPCI)December 7, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc up on Tuesday (IPCI)October 16, 2023 | msn.comIntellipharmaceutics International GAAP EPS of -$0.06October 13, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc down on Friday (IPCI)July 6, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc down on Wednesday (IPCI)June 29, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc down on Tuesday (IPCI)June 13, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc down on Monday (IPCI)April 18, 2023 | finance.yahoo.comIntellipharmaceutics International Inc. (I4AA.F)April 7, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc flat on Wednesday (IPCI)April 5, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc flat on Monday (IPCI)April 4, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc flat on Friday (IPCI)February 7, 2023 | yahoo.comIntellipharmaceutics Provides Update on Management Cease Trade Order Application and Anticipates Cease Trade OrderJanuary 13, 2023 | finance.yahoo.comIntellipharmaceutics International Inc. (IPCIF)August 30, 2022 | thestreet.comChanges at the Top for Endo Could Benefit Its Smaller PartnersAugust 23, 2022 | reuters.comIntellipharmaceutics International IncJuly 23, 2022 | finanznachrichten.deIntellipharmaceutics International Inc.: Intellipharmaceutics Announces Second Quarter 2022 ResultsJuly 21, 2022 | finance.yahoo.comIntellipharmaceutics Announces Second Quarter 2022 ResultsJuly 15, 2022 | ca.finance.yahoo.comStocks in play: Intellipharmaceutics International Inc.April 14, 2022 | finanznachrichten.deIntellipharmaceutics International Inc.: Intellipharmaceutics Announces First Quarter 2022 ResultsApril 14, 2022 | stockhouse.comIntellipharmaceutics Announces First Quarter 2022 ResultsFebruary 28, 2022 | finanznachrichten.deIntellipharmaceutics International Inc.: Intellipharmaceutics Announces Fiscal Year 2021 ResultsJanuary 13, 2022 | finanznachrichten.deIntellipharmaceutics International Inc.: Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene KeirsteadJanuary 7, 2022 | nasdaq.comIntellipharmaceutics International Inc (IPCIF)See More Headlines Receive I Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellipharmaceutics International and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorBusiness Services Industry Wireless Telecommunications Sub-IndustryN/A Current SymbolTSE:I CUSIPN/A CIKN/A Webwww.intelsat.com Phone+1-416-7983001FaxN/AEmployees1,195Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares30,156,000Free FloatN/AMarket CapC$97.40 million OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesIsa Odidi Ph.D.Chairman of the Board, Chief Executive OfficerAmina Odidi Ph.D.President, Chief Operating Officer, DirectorAndrew PatientChief Financial OfficerJohn N. AllportVice President - Legal Affairs and Licensing, Secretary, DirectorPatrick N. Yat Ph.D.Vice President - Pharmaceutical Analysis and ChemistryKenneth KeirsteadIndependent DirectorBahadur MadhaniIndependent DirectorEldon R. Smith M.D. (Age 75)Independent Director More ExecutivesKey CompetitorsZCL CompositesTSE:ZCLNeuLionTSE:NLNCIBT Education GroupTSE:MBAReitmansTSE:RETCO2 SolutionsCVE:CSTView All Competitors I Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Intellipharmaceutics International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intellipharmaceutics International investors own include QuickLogic (QUIK), VBI Vaccines (VBIV), NeuLion (NLN), Micron Technology (MU), Mallinckrodt (MNK), Intellipharmaceutics International (IPCIF), Fitbit (FIT), Clean Commodities (CLE), Calithera Biosciences (CALA) and BlackBerry (BB). How do I buy shares of Intellipharmaceutics International? Shares of I stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:I) was last updated on 6/12/2024 by MarketBeat.com Staff From Our PartnersYour Special Report - Top 7 Summer StocksSummer is almost Here! I would like to give you a special report that could help boost your portfolio this sum...StockEarnings | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe Hidden Tax Advantages of America’s #1 Inheritance StockWall Street Millionaire: BUY "America's #1 Legacy Stock" The man CNBC called "The Prophet" bought AAPL at $...Stansberry Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellipharmaceutics International Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellipharmaceutics International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.